1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,022 | 0,024 | 16:52 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Genflow reports sustained safety in aged dog gene therapy trial | 3 | Investing.com | ||
| Mi | Genflow Biosciences - Update on the Dog Study | - | RNS | ||
| 31.03. | Genflow Biosciences PLC Announces Total Voting Rights | 184 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / March 31, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") announces that the total issued share capital of the Company as at 31 March... ► Artikel lesen | |
| GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 31.03. | Genflow Biosciences - Total Voting Rights | 2 | RNS | ||
| 05.03. | Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications | 234 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 05.03. | Genflow Biosciences - Issue of Equity & PDMR Notifications | 3 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Result of GM | 226 | ACCESS Newswire | Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company... ► Artikel lesen | |
| 02.03. | Genflow Biosciences - Result of GM | 1 | RNS | ||
| 02.03. | Genflow Biosciences PLC Announces Receipt of First Tranche of Grant | 271 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 02.03. | Genflow Biosciences - Receipt of First Tranche of Grant | 2 | RNS | ||
| 12.02. | Genflow meldet positive Zwischenergebnisse bei Gentherapie-Studie mit Hunden | 23 | Investing.com Deutsch | ||
| 12.02. | Genflow reports positive interim results from dog gene therapy trial | 1 | Investing.com | ||
| 12.02. | Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study | 250 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 12.02. | Genflow Biosciences - Preliminary Interim Results From Dog Study | - | RNS | ||
| 11.02. | Genflow Biosciences to seek approval for potential equity raise | 4 | Investing.com | ||
| 11.02. | Genflow Biosciences strebt Zustimmung für potenzielle Kapitalerhöhung an | - | Investing.com Deutsch | ||
| 11.02. | Genflow Biosciences PLC Announces Notice of GM | 253 | ACCESS Newswire | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
| 11.02. | Genflow Biosciences - Notice of GM | - | RNS | ||
| 30.01. | Genflow Biosciences PLC Announces Holding(s) in Company | 306 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason... ► Artikel lesen | |
| 28.01. | Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities | 258 | ACCESS Newswire | LONDON, UK / ACCESS Newswire / January 28, 2026 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION... ► Artikel lesen |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,024 | -22,29 % | Medigene: Zurückziehung - 18.11.2025 | ||
| CRISPR THERAPEUTICS | 43,315 | -2,05 % | Quant ratings on Cathie Wood's top holdings: TSLA, CRSP, AMD, and TEM | ||
| CO.DON | 0,014 | -20,59 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,170 | +1,04 % | PacBio Announces the Appointment of Chris Gibson to the Board of Directors | MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher... ► Artikel lesen | |
| TME PHARMA | 0,069 | +16,36 % | TME Pharma NV: TME Pharma extends financial runway to over 12 months | TME Pharma extends financial runway to over 12 months Berlin, Germany, March 9, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,305 | -1,09 % | Denali Therapeutics Inc.: Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) | Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle technologyResults from ongoing Phase 1/2 study in patients with... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,083 | +3,77 % | Replenish Nutrients Holding Corp: Replenish Nutrients appoints Glover as special adviser | ||
| GLOW LIFETECH | 0,025 | -12,50 % | Glow Lifetech Corp.: Glow Lifetech Reports Fourth Quarter and Full Year 2025 Financial Results; 146% YoY Revenue Growth and Second Consecutive Quarter of Positive Cash Flow | Toronto, Ontario--(Newsfile Corp. - April 8, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the fourth... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,242 | -3,22 % | Voyager Therapeutics, Inc.: Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results | - Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans: expect two I.V.-delivered neuro gene therapies... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,012 | +50,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| NEOVACS | 0,001 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 08.04.2026 | Das Instrument B4A1 CH0208062627 MEIER TOBLER GRP AG NAM. EQUITY wird cum Kapitalmassnahme gehandelt am 08.04.2026 und ex Kapitalmassnahme am 09.04.2026 The instrument B4A1 CH0208062627 MEIER TOBLER... ► Artikel lesen | |
| BIOAGE LABS | 14,960 | -1,58 % | BioAge Labs, Inc.: BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | Positive interim Phase 1 data for BGE-102, a potent, structurally novel, orally available, brain-penetrant small-molecule NLRP3 inhibitor, demonstrating potential best-in-class reductions in inflammatory... ► Artikel lesen | |
| BIOVAXYS TECHNOLOGY | 0,048 | 0,00 % | BioVaxys Technology Corp.: BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda ) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC) | Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent ChemotherapyVancouver, British Columbia--(Newsfile... ► Artikel lesen | |
| TELO GENOMICS | 0,037 | -6,41 % | Telo Genomics Corp.: Telo Genomics Announces Appointment of John Farlinger as CEO and Chairman | Vancouver, British Columbia--(Newsfile Corp. - March 31, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and... ► Artikel lesen | |
| ALTERITY THERAPEUTICS | 0,004 | -33,33 % | ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program | MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing... ► Artikel lesen |
GENFLOW BIOSCIENCES PLC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,005 (+26,47 %) liegt der Kurs bei 0,022 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLOW BIOSCIENCES PLC finden Sie auf Wallstreet Online.